If you've been researching GLP-1 medications and stumbled across both Zepbound and Mounjaro, you might be wondering why they sound so similar — and whether one is actually better than the other. The short answer is surprisingly simple: they contain the exact same active ingredient. But the longer answer matters a lot for your wallet, your insurance coverage, and your treatment goals. Let's break it all down.
The Core Difference: Same Drug, Two Brand Names
Both Zepbound and Mounjaro contain tirzepatide, a once-weekly injectable medication made by Eli Lilly. Tirzepatide is a dual GIP/GLP-1 receptor agonist — meaning it activates two separate hormone pathways (glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1) to regulate blood sugar, slow digestion, and reduce appetite. It's this dual-action mechanism that makes tirzepatide particularly powerful compared to single-receptor GLP-1 drugs like semaglutide (Ozempic/Wegovy).
So if they're the same molecule, why do two brand names exist? Because the FDA approves drugs for specific indications, and Eli Lilly sought separate approvals for separate patient populations:
- Mounjaro — FDA-approved in May 2022 for type 2 diabetes management. Prescribed to help control blood sugar in adults with T2D, alongside diet and exercise.
- Zepbound — FDA-approved in November 2023 for chronic weight management. Prescribed for adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related condition like high blood pressure or sleep apnea.
Same pen, same doses, same tirzepatide molecule — different label, different indication, different insurance pathway.
Dosing: Identical Across Both Brands
Because the active ingredient is identical, the dosing schedule is the same for both Zepbound and Mounjaro. Both are administered as a subcutaneous injection once per week and come in the same dose tiers:
- 2.5 mg (starting dose, used for the first 4 weeks)
- 5 mg
- 7.5 mg
- 10 mg
- 12.5 mg
- 15 mg (maximum dose)
Your prescriber will typically start you at 2.5 mg and titrate up every four weeks as tolerated, aiming to find the lowest dose that gives you meaningful results with manageable side effects. This slow titration is key to reducing nausea, vomiting, and GI discomfort — the most common complaints with tirzepatide.
How Much Weight Can You Actually Lose?
Tirzepatide's clinical trial results are genuinely impressive. In the SURMOUNT-1 trial, participants on the highest dose (15 mg) lost an average of 22.5% of their body weight over 72 weeks. Across all doses in the SURMOUNT program, the average weight loss was approximately 20.2% — nearly double what's seen with older GLP-1 medications.
To put that in perspective: for someone starting at 250 lbs, 20.2% weight loss translates to about 50 pounds. That's meaningful, life-changing weight loss for many people.
In a landmark 2025 head-to-head study (SURMOUNT-5), tirzepatide was directly compared to semaglutide 2.4 mg (Wegovy). Tirzepatide produced 47% greater relative weight loss than semaglutide — a significant difference that has reshaped how clinicians think about these two drug classes.
Important: Individual results vary significantly based on starting weight, dose achieved, diet, activity level, and metabolic factors. Clinical trial averages don't guarantee what you'll personally experience — but they give you a solid benchmark for realistic expectations.
Insurance Coverage: Where the Real Difference Lives
Here's where the Zepbound vs Mounjaro distinction actually matters in a practical, day-to-day sense: insurance coverage.
Because Mounjaro is approved for type 2 diabetes, many commercial insurance plans and Medicare Part D cover it for patients with a T2D diagnosis. Zepbound, approved for obesity/weight management, faces a much rockier coverage landscape. Many insurers still categorize weight-loss drugs as "lifestyle medications" and exclude them — even though obesity is a recognized chronic disease.
This has created a frustrating situation where two people taking the exact same drug might pay very different amounts depending on what's on their diagnosis code. Some people with both diabetes and obesity find Mounjaro covered while Zepbound is not, even though the medication in the pen is chemically identical.
As of 2026, coverage for Zepbound is expanding, but it remains inconsistent. Always verify your specific plan's formulary before assuming coverage.
Can Your Doctor Prescribe Mounjaro Off-Label for Weight Loss?
Yes — and many do. Because both drugs contain tirzepatide, a physician can legally prescribe Mounjaro "off-label" for weight management in patients who don't have type 2 diabetes. However, insurance is unlikely to cover it for that indication without a diabetes diagnosis, and some pharmacies or plans may flag it. Zepbound is typically the cleaner path if weight management is your primary goal and you can secure coverage or afford out-of-pocket costs.
Side Effects: Expect the Same Profile
Since the active ingredient is identical, the side effect profile of Zepbound and Mounjaro is the same. The most common side effects are gastrointestinal:
- Nausea (most common, especially in the first few weeks)
- Diarrhea or constipation
- Vomiting
- Stomach pain or bloating
- Decreased appetite (which is also part of how it works)
Most people find GI side effects improve significantly after the first few weeks as their body adjusts. Eating smaller meals, avoiding high-fat foods, and staying hydrated can help. Rare but serious risks include pancreatitis and, in rodent studies, thyroid C-cell tumors — which is why tirzepatide carries a black box warning for patients with a personal or family history of medullary thyroid carcinoma or MEN2.
Zepbound vs Mounjaro vs Wegovy: How Do They Compare?
If you're weighing tirzepatide (Zepbound/Mounjaro) against semaglutide-based options like Wegovy or Ozempic, the efficacy data consistently favors tirzepatide for weight loss. Semaglutide averages about 13.7% body weight loss over 68 weeks in the STEP trials, compared to tirzepatide's ~20.2%. The dual GIP/GLP-1 mechanism appears to drive meaningfully greater fat loss.
That said, semaglutide has a longer track record, broader insurance coverage for weight management (Wegovy specifically), and extensive cardiovascular outcome data (the SELECT trial showed a 20% reduction in major cardiovascular events). Some people also tolerate semaglutide better, particularly those who experience significant GI side effects on tirzepatide. There's no universally "right" answer — the best drug is the one you can afford, tolerate, and stay on consistently.
Quick Summary: Zepbound vs Mounjaro at a Glance
- Active ingredient: Both contain tirzepatide (same molecule)
- FDA approval: Mounjaro for T2D; Zepbound for weight management
- Dosing: Identical (2.5 mg to 15 mg, once weekly)
- Side effects: Identical profile
- Coverage: Mounjaro more often covered for T2D patients; Zepbound for obesity (still inconsistent)
- Weight loss data: ~20.2% average across SURMOUNT trials
If you're trying to figure out how much weight you might lose on tirzepatide — whether you're prescribed Zepbound or Mounjaro — personalized estimates are far more useful than generic averages. Use our free GLP-1 weight loss calculator at GLP1Calc to get a projection tailored to your starting weight, goal, and timeline.
The Bottom Line
The difference between Zepbound and Mounjaro is primarily administrative, not pharmacological. They are the same drug with the same mechanism, same dosing, and same side effects. The distinction that matters most in real life is insurance coverage and the indication on your prescription. Work with your prescriber and insurance navigator to figure out which path makes the most financial and clinical sense for your situation — and don't let the two brand names confuse what is ultimately one very effective medication.